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The mucosa of the gastrointestinal tract, eyes, nose, lungs, cervix and vagina are lined by 
epithelium interspersed with mucus-secreting goblet cells, all of which contribute to their 
unique functions. This mucus provides an integral defence to the epithelium against noxious 
agents and pathogens. However, it can equally act as a barrier to drugs and delivery systems 
targeting epithelial passive and active transport mechanisms. This review highlights the 
various mucins expressed at different mucosal surfaces on the human body, and their role in 
creating a mucoid architecture to protect epithelia with specialized functions. Various factors 
compromising the barrier properties of mucus have been discussed, with an emphasis on how 
disease states and microbiota can alter the physical properties of mucus. For instance, 
Akkermansia muciniphila, a bacterium found in higher levels in the gut of lean individuals 
induces the production of a thickened gut mucus layer. The aims of this article are to 
elucidate the different physiological, biochemical and physical properties of bodily mucus, a 
keen appreciation of which will help circumvent the slippery slope of challenges faced in 
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1 Introduction  
 
The mucosal barriers of the human body are integral not only to protect against 
immunological, chemical and mechanical stresses, but have also increasingly gained 
prominence for their key role in drug delivery. Mucosa consists of one or more layers of 
epithelial cells overlying a layer of loose connective tissue, the lamina propria; which is a key 
part of the mucosal immune system, and followed by the submucosa, consisting of 
submucosal glands and muscular layers. Some specialized mucosal epithelial cells (such as 
goblet cells) secrete mucus glycoproteins, which form a layer of viscoelastic mucus on the 
surface of epithelia. Mucus per se is a semi-permeable network that enables the exchange of 
nutrients, water, gases, hormones and gametes, whilst being impermeable to most bacteria 
and pathogens due to its steric obstruction and adhesion properties [1, 2].  Cell surface 
mucins are a prominent feature of the apical glycocalyx of all mucosal epithelia [3].  
 
The properties and functions of mucus secretions are adapted to suit the anatomical location, 
and can change (as cause or consequence) in disease states where mucus hypersecretion or 
altered mucin expression is observed [3, 4]. Indeed, the differing compositions of the mucosa 
and mucus of the eye, nose, lower respiratory tract, gastrointestinal tract, cervix and vagina 
are all individually unique and adapted to perform the functions of these barriers seamlessly, 
whilst simultaneously protecting the underlying epithelium. For instance, the epithelia of the 
respiratory tract form a mucociliary escalator [4] that aids the movement and expulsion of 
trapped inhaled foreign bodies, whereas the transmembrane mucins tethered in the periciliary 
layer (PCL) form a sieve restricting particles greater than 40 nm from translocating into the 
PCL, thereby maintaining sterility [5, 6]. In turn, a double-layer mucus architecture in the 
hostile zones of the stomach and colon protect the underlying lining from acid, enzymes 
(pepsin and proteases) and microbial aggressors [7, 8]. Endogenous hormone secretion from 
the epithelia of the cervix and vagina also changes the viscoelasticity of cervical mucus in 
different stages of the menstrual cycle, to either promote or prevent conception [9]. Dietary 
influences have also been observed to modulate the colonic mucus; low-fibre diets, for 
instance, have been shown to lead to thinning of mucus owing to associated bacterial 
colonisation [10, 11]. This thinning exposes the epithelium to bacterial contact and 
translocation into the mucosa, eliciting an immunological response and further damage and 
inflammation, as seen in ulcerative colitis [12]. These properties of mucus in the healthy 
state, however, make it an excellent guard against immunological as well as chemical and 
mechanical damage, thereby allowing the mucosa to carry out its normal physiological 
functions. 
 
While mucus precludes the permeation of drugs, proteins, peptides and nanoparticulate drug 
delivery systems [13, 14], certain capsid viruses have been observed to diffuse through 
cervicovaginal mucus at rates similar to that in water [15], implying that this barrier cannot 
restrict surface neutral particles from reaching and infecting the epithelium. Additionally, the 
mucus pore size and rheology also influence this phenomenon [16]. This property has been 
exploited towards the design of muco-inert polyethylene glycol coated nanoparticles that are 
muco-penetrating for cervico-vaginal and ocular delivery [17, 18]. Overall, this knowledge 
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can be used to design drug delivery systems to diffuse ‘upstream’ against the secretion and 
shedding of mucus to deliver drugs to epithelia.  
 
Furthermore, mucus secreting epithelia continuously secrete and turnover mucus to create a 
physiological clearance mechanism. However, this protective mechanism can also cause 
undesirable drug clearance, a common barrier to drug delivery. As such, in order to deliver 
the drug payload, and hence achieve the desired drug exposure, prolonged contact of the 
formulation at the target site is desirable. Mucoadhesive systems have been employed by 
virtue of their ability to interact with the mucin glycoprotein; whereby mucoadhesive 
excipients by swelling and interdiffusion of the polymer chains bond with mucin fibers 
through hydrogen bonding, disulfide bonding, electrostatic and/or hydrophobic interactions. 
An in-depth review of mucoadhesion as a concept to increase residence time is beyond the 
scope of this review which focuses on the physiological aspects of mucosa and mucus and 
therefore the following references [19-23] will provide the reader with greater insight in the 
area of mucoadhesion. 
 
This article reviews the mucosal histology in relation to the arrangement of goblet cells and 
submucosal glands. The biosynthesis and release mechanism of mucin from the goblet cells 
and the physiological and mechanical characteristics of the mucus lining different epithelia 
are here discussed. Additionally, the functionality of the mucus lining and its dynamic 
composition are discussed in their role of health and disease.  
 
2 Mucosa and mucus: histological, biosynthetic, biochemical and rheological 
overview 
 
The mucosal epithelium is interspersed with goblet cells which secrete mucus and protect the 
epithelial cells. If antigenic materials translocate through the epithelium, it triggers an 
immune response in the underlying lamina propria and submucosa which can comprise the 
connective tissues of the mucosa [24, 25]. The immune response is characterized by 
inflammation and epithelial destruction, exacerbating the damage. Therefore, mucus serves as 
a tenacious semipermeable barrier allowing only nutrients, gases and certain agents to 
permeate through it, while trapping noxious agents, bacteria and particles thereby preventing 
them from reaching the epithelium [2, 26]. 
 
The goblet (mucus producing) cell is ubiquitous in the mucosa consisting of single columnar 
cells intercalated in the epithelium. There are two types of mucins; the secreted gel-forming 
mucins, forming a gel layer over the epithelium and transmembrane mucins which form the 
‘glycocalyx’ at the apical surface of the epithelium. The secreted mucins as described in 
Table 1 are glycoproteins , made-up of multiple monomers which are joined together to form 
an oligomer that forms the entangled mesh like structure [27].  Transmembrane (cell-
associated) mucins which constitute the glycocalyx, are anchored to the cell surface by a 
transmembrane SEA domain (sea-urchin sperm protein, enterokinase and agrin) that 
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undergoes auto-proteolysis. The SEA domain appears to have evolved to break apart in 
response to mechanical stress, shedding the mucin without disrupting the membrane [28].  
 
These mucins have high molecular weights (1-40 x 106 Daltons) and are comprised of a 
protein core (800 amino acid residues) around 60 - 80% of which is attached to 
oligosaccharide branches (2-22 sugars in length). The number, length and amino acid 
sequence of these glycosylated domains differ between mucins [29-31]. The mucin monomer 
is about 0.2 – 0.6 μm in length with disulphide rich cysteine domains at N and C terminal 
ends. The mucin monomer has tandem repeat units of PTS (proline, threonine and serine), 
amino acid domains that are highly glycosylated. These includes  glycans such as N-
acetylgalactosamine (GalNAc) O-linked to threonine and serine and elongated by different 
monosaccharides including galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc) 
and sialic acids by the action of various glycosyltransferases and can also be sulfated. The 
PTS glycan domains are resistant to proteolysis. Each monomer is separated by ‘naked’ 
protein domains about 110 amino acid in length interspersed with cys-rich domains which 
form intramolecular disulfide bonds and avidly bind lipids which impart the hydrophobicity 
to the mucin and ultimately to the mucus [32]. The SH groups at the cysteine domains, helps 
establishing intermolecular disulphide bridges between monomers to form dimers and trimers 
at the C and N terminals, respectively. The sialic acid and sulfate residues are fully ionized at 
pH>2.6, thereby conferring a negative charge to the mucin molecule at higher pH. Sialylation 
occurs predominantly in colonic mucins and has been shown to contribute to degradation 
resistance of mucins to colonic bacteria. An increasing gradient of sialo and sulfomucins has 
been observed in human, rat, rabbit and pig large intestine; correlating well with the denser 
bacterial population towards the distal regions [33, 34].  
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Table 1: The secreted and transmembrane mucins at various epithelial surfaces 
Abbreviations: NA, not applicable; NF, not found  
 
Mucus Mucosal surface 































         
Surface/crypt NF  [34] NF  MUC 5AC 
[34] 
MUC 2[34] MUC 2[34] MUC 5AC 
(MUC2)[36]  
MUC 5AC[37] MUC 5AC,  
MUC 5B[38] 
Gland MUC 5B 
[34] 
MUC 2[35] MUC 6[34] MUC 6[34] NF[34] MUC 5B[36] MUC 5B[37] MUC 6[38]  
Paneth cells NA [34] NA  NA[34] MUC 2[34] NA NA    
Transmembra
ne mucins on 
epithelial cells 
MUC1 
MUC 16[34]   
- MUC 1[34] MUC 1, MUC 3, 
MUC 4, MUC 12, 
MUC 13, MUC 
17[34] 
MUC 1, MUC 3, 
MUC 4, MUC 12, 




MUC1, MUC 4, 
MUC 16 [37] 
MUC1, MUC4, 















Besides mucin, which is the main component responsible for the structure and functions of 
mucus, a number of other components are present within the mucus layer. Mucus is 
composed of water (95%), mucin (glycoproteins which provide the gelling and viscoelastic 
properties), lipids, proteins, sloughed epithelial cells, DNA and inorganic salts. Amongst the 
main important proteins secreted into the mucus layer are secretory immunoglobulin A 
(SIgA), lysozyme, lactoferrin, FCGBP and trefoil peptides [40]. SIgA is secreted by the 
epithelial cells into the mucus layer and serves to inhibit epithelial attachment of antigens 
capable of eliciting an immune response. FCGBP is covalently attached to mucins and its 
exact role is not known. It is probably responsible for the binding of IgG allowing its 
diffusion through the mucus to translocate antigens to be presented to the antigen-presenting 
cells (APC) for immune protection [41]. Trefoil peptides are co-secreted along with mucus by 
mucus-producing cells in the gastrointestinal tract and have been involved in cell migration 
from the crypts and cell repair after damage, a process known as ‘epithelial restitution’ [42]. 
 
 
As seen in figure 1, the polymeric mucin assembly starts in the endoplasmic reticulum (ER), 
where the non-O-glycosylated mucin monomer forms dimers [41] via disulphide bonds 
formed between C- terminals. In the Golgi apparatus, mucin dimers are O-glycosylated and 
then multimerized by disulphide bonds formed between N-terminal domains. In the case of 
MUC5B, multimers form between dimers of dimers [43] whereas multimers of MUC2 form 
trimers of dimers [44]. The mucin multimers are then packed in an ordered state within the 
secretory granules in the presence of high concentration of Ca2+ and H+. The H+ neutralizes 
the otherwise negatively charged sialic acids and the Ca2+ cross-links the remaining 
negatively charged glycans (sulphate groups)  [45]. For instance, the MUC2 monomeric 
building block has a mass of approx. 2.5MDa when fully glycosylated and is polymerized by 
C-terminal dimerization and N-terminal trimerization, resulting in the formation of enormous 


















Figure 1: Assembly of the MUC2 mucin in the goblet cell. ER, endoplasmic reticulum; 
TGN, trans-Golgi network. Reprinted with permission from [46].  
 
 
When mechanically or chemically stimulated, goblet cells respond promptly whereby most of 
the mucus granulae in the goblet cell theca are fused and released, emptying the whole cell 
interior leaving a thin cell which is sometimes mistaken for the reduced goblet cell count in 
inflammatory bowel disease [46, 48]. When the mucin  is secreted, Ca2+ and H+ diffuse away 
and the granule swells explosively expanding about 500-fold in volume in 50 ms [49]. In the 
small intestine, for example, mucus expansion upon secretion is facilitated by increasing pH 
and sequestration of Ca2+ through release of bicarbonate ions (HCO3
-) by cystic fibrosis 
transmembrane conductance regulator (CFTR) in the epithelial cell [44], as depicted in 
Figure 2. The mucin sheets which are attached to the epithelium are then released by 
endogenous protease, Meprin β. Meprin β is anchored in the enterocyte apical membrane and 
cannot access the mucin goblet cell anchor from this position. To interact with MUC2 it 
needs first to be released by extracellular cleavage, allowing it to diffuse into the mucus. The 
release of anchored Meprin β is controlled and triggered by exposure to bacteria as evidenced 
by germ-free mice which have the small intestinal mucus attached to the epithelia but when 





Figure 2: The mucin-release mechanism in the small intestine. Reprinted with permission 
from [51]. 
 
The complex interplay of glycans, hydrophobicity, lipids, disulphide bonding and molecular 
weight of the mucin oligomer, when released and coming in contact with water, gives mucus 
its viscoelastic gel like properties, since mucins bind and retain significant amounts of fluid. 
At the macroscopic (bulk level) mucus is a thixotropic gel; under low shear it acts like an 
elastic solid and under high shear as a viscous liquid. Mucus viscoelasticity is of critical 
importance for the protective and lubricant functions of mucus [16]. The bound lipids may 
also form numerous low-affinity bonds between overlapping mucins thereby increasing the 
viscoelasticity of the mucus gel. Delipidation of mucins by lyso-lecithin and treatment with 
N-acetyl cysteine which breaks S-S bonds significantly decreased mucus viscoelasticity 
whereas exposing mucin to pH<4 greatly increases the hydrophobicity by exposing 
hydrophobic domains within the protein core, causing the mucin bundles to aggregate and 
increasing its viscoelasticity [52, 53].  
 
When the mucus layer undergoes shearing action, as seen by the blinking of eyes, copulation, 
coughing and peristalsis, a lubricating slippage plane of mucus forms between the two 
surfaces while keeping the gel layers adherent to the surface intact (i.e entangled and 
unstirred) thereby preventing the diffusion of nanoparticles [16]. The viscosity of human 
mucus is 104 - 106 times that of water and is greatly reduced when subjected to high shear. 
This macrorheological property of mucus, has been used as reference when studying the 
barrier properties of mucus at various mucosal surfaces and has helped to select animal 
models closest to humans [16]. The pig is a popular model for characterizing gastrointestinal 
tract mucus; having both the adherent layer resistant to shear and loosely bound layer that is 
shear complaint and similar in mucin molecular weight [54]. While rat mucus is 10-fold less 
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viscoelastic than that of human, it is commonly used in studying nasal, lung and 
gastrointestinal mucus owing to its similarity in slope log viscosity vs. log shear rate [16, 55]. 
 
The duodenal mucus is less viscoelastic than gastric and colonic and this is reflected by the 
fact that it traps and propels the particles by its property of viscidity whereas the adherent 
layer of colonic mucus acts as a size exclusion sieve not allowing bacteria > 0.5μm to come 
in contact with the epithelia [12]. The optimal viscoelasticity of the gel layer on the nasal and 
pulmonary mucosa also allows for sufficient contact between the cilia and the mucus gel; the 
shear force exerted by the cilia reduces the mucus viscoelasticity and facilitates transport of 
the mucus towards the mucopharynx for ingestion in the GI tract [56]. The ovulatory mucus 
owing to its lower viscoelasticity, promotes the motility of sperm whereas the non-ovulatory 



































3 The slippery slope: variations in mucus along the gastrointestinal (GI) tract 
 
The gastrointestinal wall is composed of four different layers: the mucosa, the 
submucosa, the muscularis and the serosa. The mucosa is further subdivided into three 
main layers: the muscularis mucosa, lamina propria and the epithelium. The mucus 
largely establishes the first barrier for absorption through the gastrointestinal tract. Figure 




Figure 3: The organization of epithelium and mucus in the gastrointestinal tract. Reprinted 




3.1  Mucosa and mucus of the mouth, esophagus, small and large intestine 
 
The buccal mucosa (the inner lining of the cheek) and sublingual mucosa comprises the 
epithelium, lamina propria, submucosa and muscularis mucosa. This mucosa is lined by non-
keratinized stratified squamous epithelium, which consists of 40–50 cell layers (500–600 μm 
thickness), which migrate from the basal layer to the superficial layer, and protect the 
underlying tissue against fluid loss and entry of potentially harmful environmental agents [60, 
61]. The intercellular spaces of the epithelia have cytokeratin protein [62], small amounts of 
ceramides and neutral but polar lipids, mainly cholesterol sulfate and glucosylceramides [63, 
64].  
 
Saliva is secreted by three major salivary glands (parotid, submaxillary and sublingual). 
Saliva mainly consists of water (95–99% per weight), enzymes, inorganic salts, lipids, and 
mucins. In the mouth, the salivary glands produce MUC5B and MUC7, which lubricate 
ingested food for passage through the esophagus forming a salivary film of average thickness 
between 70 and 100 μm on the buccal epithelium [59, 65, 66]. The salivary mucin, MUC7 
which is not oligomerized, is not thought to contribute towards mucus like properties. 
However, it has inherent direct candidacidal activity [67, 68]. MUC5B's complex structure 
allows it to interact with an array of different salivary proteins and microbes to maintain a 
healthy oral cavity. Streptococcus mutans is a cariogenic bacteria that attaches to the tooth 
surface and damages the enamel through release of acidic metabolites from sucrose 
utilization. MUC5B binds to S. mutans and decreases surface attachment and biofilm 
formation thereby playing an anti-cariogenic role [69]. 
 
 
The esophageal mucosa has a surface area of about 235cm2 in man and acts as a conduit for 
the passage of food to the stomach [70]. The pH within the esophagus is similar to that of the 
saliva pH 6-7 and is maintained by the bicarbonate secretion from the esophageal submucosal 
glands (SMGs). SMGs are present in the submucosa of human, pig and dog which have a 
non-keratinized stratified squamous epithelium and are absent in rodents (keratinized 
stratified squamous epithelium) [71, 72]. The SMGs also secrete a mucin like substance 
which is primarily neutral in nature and hence loosely bound in comparison to acidic mucin 
which has a tendency to form an adherent layer as seen in the large intestine. The SMGs may 
be responsible for the luminal acid clearance in cases of gastroesophageal reflux. The 
unstirred water layer resident on the esophageal epithelium is estimated to be 30 μm thick 
and does not account for mucus like substance; which is secreted in quantities so low in 
comparison to stomach that it cannot afford protection to the underlying epithelial cells [72, 
73].  
 
The gastric mucosa consisting of a single layer of columnar epithelial cells, is resilient to the 
effects of proteolytic enzyme pepsin and hydrochloric acid; owing to the impervious nature 
of the double layer mucus architecture. The surface epithelial cells secrete bicarbonate and 
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foveolar cells in the neck of the gastric pits secrete MUC5AC, creating a pH gradient from 
the acidic lumen (pH 1-2) to neutral pH at the cell surface [74, 75] whereas MUC6 is 
produced in the glands and is secreted together with hydrochloric acid and pepsin [76]. The 
estimated surface area of the human gastric mucosa is 500 cm2 and is lined by the epithelial 
(mucus) and glandular cells [70].  
 
Interestingly, these gland secretions are able to cross the surface of the inner mucus layer 
through what looks like temporary channels. Immunohistochemical studies have shown that 
the two layers, MUC5AC and MUC6, are arranged in alternating layers, whereby MUC5AC 
appears adjacent to the surface epithelium and with MUC6 acting as a barrier towards the 
back-diffusion of hydrochloric acid and pepsin. The higher the concentration of mucin, the 
greater the viscoelasticity and thickness of the mucus layer, hindering the back-diffusion of 
hydrogen ions. This thick and viscoelastic mucus layer has a higher capacity to retain 
bicarbonate released into the mucus layer from the mucosa. Additionally, the acidic pH 
(pH<2) keeps the adherent mucus in gel state probably owing to aggregation of mucin fibers 
[60-62]. The gastric mucin together with the bicarbonate buffer and high concentration (25% 
dry weight) of  hydrophobic phospholipids is responsible for the first line of gastric mucosal 
defence that prevents or slows down H+ back diffusion and stomach self-digestion [8]. Co-
secreted trefoil peptides also play a role in maintaining epithelial health by promoting 
epithelial restitution and increasing mucus viscoelasticity (TFF 1and 3). TFF2 increases the 
viscosity of the mucosal layer and stabilizes the gel network [77]. 
 
Ulcerogenic substances such as aspirin and NSAIDs, by inhibition of prostaglandin D2, 
disrupt the mucus gel and the phospholipid layer, promoting mucosal injury. Furthermore, 
Helicobacter pylori triggers proteolysis and lipolysis of the mucin-lipid network, decreasing 
its viscosity and impairing the defense mechanism establishing a strong causal relationship to 
gastric ulcers [78, 79]. Idiopathic peptic ulcers are thought to be caused by aberrant mucin 
secretion, age, smoking or acid hypersecretion [80]. Certain bacterial lipopolysaccharides 
(LPS) for e.g Pseudomonas aeruginosa and Hemophilus influenza upregulates the expression 
of MUC5AC but reduces its glycosylation and sulfation thereby compromising its protective 
nature [81].  While the main role of proton pump inhibitors (PPIs) is to reduce gastric acid 
secretion by inhibiting the H+-K+ ATPase pump in the parietal cells, PPIs like leminoprazole 
[82] and rabeprazole [83] have been found to increase secretion and viscosity of gastric 
mucus thereby further enhancing its barrier forming properties. 
 
In the intestinal tract, the transmembrane mucins MUC3, MUC4, MUC12, MUC13 and 
MUC17 are constitutively expressed, whereas MUC1 and MUC16 are upregulated in 
response to infection and cancer [51]. The transmembrane mucins play a role in cell 
signalling and MUC16, the longest mucin of about 700 nm in length, probably senses the 
extracellular environment and sends signals to the immune system. Through this mechanism, 
also thought to promote epithelial barrier integrity MUC17 executes a defensive role 




MUC2 is the primary mucin-forming mucus of both small and large intestine, however, the 
biochemistry in the formation of the loose mucus is totally different between the two. The 
loosely bound nature of the small intestinal mucus is dependent on the CFTR whereas that of 
the colon relies on the endogenous proteases converting the inner adherent mucus into 
loosely bound mucus [50, 86]. In a study by Johansson and co-workers [7], it was established 
that there was a difference in MUC2 concentration between the firm and loose layers with a 
lower proportion in the latter. The reduced MUC2 in the loose layer is due to proteolytic 
cleavages as confirmed by applying protease inhibitors mixture inhibiting serine and cysteine 
proteases to the firm layer in vivo. A decreased replenishing rate of loose mucus was 
observed but firm mucus was not affected and there was an increased MUC2 concentration in 
the loose layer. This argument is further strengthened by the fact that the presence of a loose 
mucus layer in colon of germ free mice suggests that the formation of the loose mucus is due 
to endogenous proteases. Additionally, when a firm mucus pellet was treated with trypsin (a 
serine protease) of pancreatic origin for 3 hours, it resulted in a volume expansion of the 
pellet. 
 
The small intestinal mucus layer is relatively impenetrable as it traps and wraps pathogens 
moving them distally to the colon with the help of the migrating motor complex (MMC), 
which is a contractile activity of the muscles stimulated by the nerves. This ability to trap 
bacteria comes from a property of mucus known as ‘viscidity’ [2]. This is further enhanced 
by the ability of mucus layer to limit the diffusion of bacteria while simultaneously 
generating a gradient of antibacterial proteins and peptides secreted by the Paneth cells [87, 
88]. The Paneth cells at the bottom of the crypt not only secrete antibacterial peptides and 
lysozyme, but also scaffolding proteins such as MUC2. Combined secretion of mucins and 
fluid from the crypts help to ensure that this compartment remains relatively depleted of 
bacteria [89]. 
 
The adherent firm layer in the large intestine is free from bacteria acting as a size exclusion 
filter, not allowing bacteria of diameter less than 0.5 μm to permeate through and reach the 
epithelium.  The bacterial count in the small intestine is 102-104 cfu/ml and increases distally 
towards the ileum thus explaining the loosely bound nature of small intestinal mucus which is 
relatively sterile in comparison to the colon [90, 91]. The colonic mucus harbors a large 
biodiversity of microbiota (1012-1014 cfu/g) which have an important role in metabolism. At 
50 μm (mouse) or 200 μm (human) distance from the underlying epithelium, endogenous 
protease activities convert the inner mucus layer into the outer non-attached mucus that is 
slowly expanded 2–3-fold in volume [7, 12]. 
 
Germ-free animals have a penetrable (defective) colonic inner mucus as is also the case for 
animals lacking the NHE3 (sodium–hydrogen exchanger 3) ion transporter or cytokine 
interleukin (IL)-10 [12, 91]. The mucus probably becomes penetrable due to an ionic 
imbalance or digestion by proteolytic enzymes released by the immune cells e.g neutrophil 
elastase. The bacteria in such animals are in direct contact with the epithelium eliciting an 
inflammation as seen in MUC 2 deficient mice. In these models inflammation occurs almost 
spontaneously as opposed to that seen in DSS (dextran sodium sulphate) models of colitis 
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where rodents are given 2-5% DSS over a period of 5 days.  Bacteria are seen in contact with 
the epithelium within the first 12 hours but inflammation ensues later being different from the 
models discussed earlier. The mechanism of DSS colitis differs in that, complexes of DSS 
and fatty acids are formed in mucus, which translocate into the epithelial cell damaging it and 
eliciting colitis. The penetrable mucus layer, as also observed in patients suffering from 
ulcerative colitis, allows a greater than usual number of bacteria to come in contact with the 
epithelia thus overwhelming the immune system and initiating the recruitment of 
inflammatory cells and cytokines [92]. 
 
 
3.2 GI mucus thickness and its relation to turnover 
 
The thickness of the gastrointestinal mucus layer is a consequence of the balance between its 
secretion rate and its erosion through bacterial enzymatic digestion or mechanical shear. The 
resistance to proteolytic activity has been found only in the glycosylated regions [93].  
In vitro measurements with a method not employing organic solvents/fixatives does not cause 
shrinkage and dehydration of the mucus layer as measured in rat gastric mucus thickness 
approximately 144±52 μm which is 5-fold greater than 39±14 μm measured when using 
fixatives [94]. In vitro studies have shown a thicker gastric mucus relative to caecum and 
colon whilst in vivo studies using micropipette and intravital microscope on the contrary have 
shown the highest mucus thickness in the colon 830 ± 110 μm relative to other regions in the 
GIT [95-97]. Large differences in the mucus thickness have been seen when using in vitro vs 
in vivo methods probably owing to the fact that the loose mucus layer gets washed away in 
the process of preparing the histological specimen. In the human colon, the mucus thickness 
has been reported to increase from proximal to the distal regions in the rectum where the 
bacterial load is greatest thus requiring greatest protection [60]. These reported values are 
presented in Table 2 where interspecies comparisons can also be made using the same 
histological method for rat, rabbit, pig and human. 
 
The mucus turnover along the gastrointestinal tract of humans has been reported between 24-
48h [20] and correlates with the colonic transit time in humans, measured between 26-50 
hours [98]. Mucin glycans in mice have been labelled by N- azidoacetyl galactosamine 
(GalNAz). The investigation of the colon demonstrated that crypt goblet cells were labelled 
very slowly whereas the goblet cells on the surface have faster mucin biosynthesis and 
secretion. Goblet cells at the luminal surface epithelium had fastest biosynthesis of MUC2 
and secreted material 3 hours after labelling. In 3 hours, the labelled mucus was also 
observed in the outer side and this mucus was replaced by evenly stained mucus at 4 hours 
which demonstrates that the inner mucus turnover in the distal colon is 1 hour. Mucin 
secretion from the crypt goblet cells at the top of the crypt was first observed after 6 hours 
and was frequently after 8 hours. Crypt goblet cells normally release mucus when stimulated 




Table 2: Physiological parameters in different regions of the gastrointestinal tract in humans and animals 
Gastrointestinal 
Parameter 
  Mouse Rat Rabbit Pig Dog Human 
                
Stomach               
Mucus thickness (μm)               
  Fundus   31.3 (11.4) a 155.1 (85.8) a 190.7 (80.7) a 425 d 144 (52) b 
  Body  100 c 57.9 (34.8) a 124.5 (68.8) a 213.9 (87.9) a     
  Antrum   69.4 (24.8) a 277.6 (129.4) a 222.2 (112.2) a 576 d   
                
pH of mucus layer antrum            6.4 (0.24) e 
              
Mucus turnover             24-48 h g 
                
                
Small intestine               
Mucus thickness (μm)               
  Duodenum 200-300 c 30.6 (8.8) a 73.3 (42.6) a  25.6 (12.2) a   15.5 b 
  Jejunum   38.5 (16.4) a 94.6 (67.9) a 35.3 (17.8) a     
  Ileum   34.1 (14.9) a 147.8 (115.6) a 53.8 (22.1) a     
                
pH of mucus layer             5.5 - 7.5 f 
                
Mucus turnover             24-48 h g 
   Ileum    47-270 minutes g         
 
Large Intestine (Colon) 
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Mucus thickness (μm)               
Caecum     49.6 (31.5) a 134.4 (88.4) a 37.2 (16.1) a   36.7 b 
Ascending   150 c 65.2 (39.8) a 265.1 (125.6) a 68.1 (36.5) a   39.1 b 
Transverse         83.6 (36.2) a   57.5 b 
Descending     48.4 (30) a 63.2 (41.2) a 76.3 (56.7) a   69.6 b 
Rectum       111.5 (99.6) a 58.8 (27.9) a   101.5 b 
                
pH of mucus layer             6.3 – 6.8 f 
                
Mucus turnover     1 h         24-48 h g 
 
a –[96]  
b – [19]  
c – [7]  
d –[99] 
e – [78]  
f  – [100]  












3.3 Gastrointestinal mucins and glycosylation in disease 
 
The gastric mucus layer in gastric ulcer patients is composed of lower molecular weight 
mucin (due to proteolysis), which suggests a weaker gel structure and lower efficiency in 
protecting the underlying epithelium from the harsh conditions of the lumen [102]. The inner 
layer of the gastric mucus is made up of neutral mucins MUC5AC which have a high 
viscoelasticity owing to the acidic (pH 1-2) luminal environment, thereby preventing the 
diffusion of pepsin and Helicobacter pylori. However, H. pylori releases urease which 
neutralizes the stomach acid. Urease disrupts mucin, allowing H. pylori to diffuse through it 
[78, 79]. In response to infections with H. pylori, the viscoelasticity of gastric mucus later 
increases [103], suggesting that thicker mucus may help preventing infection by motile 
pathogens. 
 
Pro-inflammatory cytokines such as TNF-α and IL-6, via regulating the glycosyltransferase 
genes, have been shown to modify the glycosylation pattern of glycoproteins in acute and 
chronic inflammation [104]. Cytokines in inflammatory bowel disease (IBD) released as a 
result of acute or chronic inflammation, induce changes in mucin O-glycosylation. Crohn’s 
disease (CD) and ulcerative colitis (UC), two chronic forms of IBD are characterized by 
chronic inflammation of parts of the gastrointestinal tract resulting from a dysregulated 
balance between pro inflammatory (TNF-α, IL-1β, IL-8 and IL-7) and immunoregulatory 
cytokines (IL-10). Changes in mucin expression, structure and/or glycosylation are likely to 
influence the protection of the colonic mucosa [105, 106]. In this connection, several changes 
have been observed concerning mucins and the mucus layer in UC: the mucus gel layer is 
thinner than normal [95, 107] and goblet cells responsible for the synthesis of secreted 
mucins such as MUC2 are reduced in number [108]. 
   
Alterations in O-glycosylation of mucins especially sialylation and sulfation have been 
reported in UC. Histological analysis in samples from ulcerative colitis patients have shown 
an increase in sialic acid residues with depletion of O-acetylation and reduction of sulfate 
residues, which has been linked to disease severity [109].  Pro inflammatory (TNF-α, IL-1β, 
IL-8) cytokines are known modulators of mucin glycosylation [110]. Mass spectroscopy 
studies have shown that patients with active UC exhibit alterations in MUC2 glycosylation, 
characterized by an increase in small glycans and lower amounts of larger glycans [111]. The 
glycosylation modifications have been correlated to result from inflammation rather than 
genetic defects [112,]. 
 
The use of animal models allowed to understand which extent O-glycosylation contributes to 
development of UC and colorectal cancer. For instance, core-1 glycan deficient mice 
developed spontaneous colitis in the distal colon and similar to human UC [112]. More 
severe and spontaneous proximal and distal chronic colitis was observed in core-1 and core-3 
O-glycan deficient mice [113]. Studying  mucins from these mutant mice showed that core 1 
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and core 3 derived O-glycans are both necessary to maintain the colonic mucus barrier and 
protect against colitis.  
 
The viscoelastic property of mucus is key to its effectiveness as a semi-permeable barrier. 
However, changes in viscoelastic properties can trigger disease or be a consequence of other 
pathophysiological changes. Mucus can immobilize Escherichia coli, a pathogenic bacteria, 
which can come into contact with small intestinal epithelia and trigger a proinflammatory 
response leading to inflammatory bowel disease [114]. Also large parasites, such as 
Entamoeba histolytica, can proteolitically disrupt  MUC2, allowing penetration through the 
inner mucus by altering viscosity and invade the underlying epithelium [115]. Cathelicidins 
are antimicrobial peptides released by colonic epithelial cells and protect against Entamoeba 
histolytica and DSS-induced colitis. They are secreted in the presence of MUC2 and butyrate, 
a product of bacterial fermentation in the colon but not in MUC2 deficient mice. Therefore 
intact mucus barrier is essential for expression and secretion of cathelicidin related 
antimicrobial peptides which only regulates the proliferation and elimination of E. histolytica 
in the presence of MUC2 [110]. 
 
The CFTR channel preferentially secretes bicarbonate and chloride while the adenosine 
system regulates mucus hydration by inhibiting sodium reabsorption and collectively plays a 
key role in protecting the small intestine from bacterial invasion. [59]. This function of CFTR 
can be explained by the disease cystic fibrosis (CF) where there is a non-functional CFTR 
channel. This disease affects all organs producing mucus with recurrent lung infections being 
the dominant course. However, it has small intestinal effects; 10% newborns with meconium 
ileus at birth and some adults with distal intestinal obstruction syndrome (DIOS). 
Furthermore, in mice with CF, the mucus was found to be attached to the epithelium and 
impenetrable but was normalized by exposing it to about 100 mM bicarbonate [50, 87, 116]. 
Thus, the altered mucus in CF mice was attributed to a lack of bicarbonate owing to the 
dysfunctional CFTR channel. 
 
 
3.4 The role of gut microbiota in mucus homeostasis 
 
 
The GI tract is heavily colonized by bacteria and their composition varies longitudinally 
along the GI tract but also transversally from the mucosa to the lumen [11].  The gut 
microbiota are believed to derive their energy requirements from the consumption of 
carbohydrates, proteins and dietary fibres [117]. Apart from these, an alternative energy 
source for the microbiota is the glycoprotein-rich mucus layer [59]. Food is known to alter 
the GI milieu and impact drug bioavailability [118]. It may have a mucus sparing effect and 
impact bioavailability of drugs hindered by mucus. In the event of excessive mucus 
degradation, the bacteria can easily reach epithelium leading to an inflammatory response and 




Mucin-degrading bacteria were considered in a first instance as pathogens  [119] but it is now 
accepted that mucin degradation is part of a normal mucus turnover process starting a few 
months after birth [11]. Certain bacteria such as Bacteroidetes (e.g Bacteroides 
thetaiotaomicron), Ruminococcus (Ruminococcustorques and Ruminococcusgnavus), 
Actinobacteria (Bifidobacterium bifidum, Bifidobacetrium breve and Bifidobacterium 
longum) and Verrucomicrobia (Akkermansia muciniphila) have been shown to degrade 
glycosaminoglycans [120-122]. The breakdown of oligosaccharides is used by other bacteria 
to proliferate while promoting the formation of SCFAs (short chain fatty acids) which are 
beneficial to the health and metabolic machinery of  gut epithelial cells [10]. However, this 
can also promote the movement of pathogenic bacteria through normally impervious inner 
mucus layer and elicit an inflammatory reaction. 
 
Recently, Akkermansia muciniphila has been identified as mucin-degrading bacteria that 
resides in the mucus layer and it is the dominant bacterium that abundantly colonizes this 
nutrient-rich environment [123]. A. muciniphila may represent 3–5% of the microbial 
community in healthy subjects, and its abundance inversely correlates with body weight and 
type 1 diabetes in mice and humans [124, 125]. A. muciniphila does not grow on 
oligofructose-enriched media (in vitro), which suggests that complex cross-feeding 
interactions are involved in the gut where mucus and prebiotics are both present. However, it 
has been previously shown in rats that oligofructose feeding increases the number of goblet 
cells and mucus layer thickness [126]. A. muciniphila degrades human mucus [123] and it has 
yet to be elucidated whether the mucus glycans in combination with prebiotics provide for an 
energy source for this bacteria. In the absence of prebiotics, this bacterium can forage on 
mucin glycans, compromising the protective barrier.[122].  
 
This hypothesis can be further strengthened by the findings of Desai et al., [127] represented 
by figure 4 where it was shown that a fibre rich diet consisting of plant fibres as opposed to 
soluble fibres (prebiotics) are needed to prevent the microbes of the gut from feeding on the 
mucus layer. Mice fed a fibre rich diet had intact mucus layers, separating the commensals 
and pathogens from the epithelium, whereas fibre deprived mice had a high proportion of 
mucus degrading bacteria and the pathogenic bacteria in contact with the epithelium. 
Furthermore, it was observed that commensal/good bacteria are not the only ones responsible 
for preventing colonization by pathogens such as Citrobacter rodentium. A diet rich in fibre 
provides the necessary energetic resources preventing this pathogen from translocating 






Figure 4: Model of how a fiber-deprived gut microbiota mediates degradation of the colonic 




3.5 Diffusion across GI mucus and its implication on drug delivery 
 
 
In the case of pig gastric and intestinal mucus, a molecular weight increase (up to 168 kDa) in 
peptides or proteins has shown to reduce diffusion [1, 13, 128]. The disruption of the mucus 
barrier (cleavage of disulphide bond) by mucolytic agent N-acetylcysteine significantly 
increased permeation of proteins through mucus [13]. Lysozyme diffusion in gastric mucus 
was slower than in cervicovaginal mucus which shows that differences in mucus properties 
contribute to this effect [15]. Considering the potential role of proteases found in mucus in 
peptide/protein digestion, means this can change the overall diffusion, particularly when 
experiments are conducted using fluorescent markers bound to specific aminoacids [1]. 
Anionic peptides seem to better diffuse across gastric mucus compared to cationic peptides, 
however, with a zero net charge is not restricted by mucus, highlighting that charge 
distribution on the surface of a protein or a particle play a significant role in terms of 
interactions with mucin [129]. 
 
Boegh et al., [14] studied the diffusion of peptide and hormones across biosimilar mucus and 
porcine intestinal mucus. The biosimilar mucus is composed of mucin, bovine serum albumin 
(BSA), polyacrylic acid (PAA), cholesterol, phosphatidylcholine and linoleic acid. Both 
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biological matrices reduced the permeation of the selected peptides, <5000 Da (octreotide, 
desmopressin, vancomycin, novicidin and plectasin) and hormones (estradiol and 
testosterone) to varying degrees. The reduction in peptide permeation was decreased 
depending on the cationicity and hydrogen bonding capacity of the permeant as demonstrated 
in biosimilar mucus. However, there was larger inter sample variation in the porcine 
intestinal mucus. Testosterone is a small lipophilic molecule and the slight reduction in 
diffusion could be attributed to its ability to form monovalent, low affinity interactions [130] 
while other proteins like antibodies or viral enveloped particles may form polyvalent 
interactions with the hydrophobic parts of mucin thereby greatly slowing their diffusion. 
 
Interestingly, it may seem that colonic mucus due to its greater mucin concentration of 5% 
versus ~1% of ovulatory cervical mucus would prevent non-mucoadhesive particles of 500 
nm from diffusing through the pores of the mucus mesh. However, on the contrary the 
increased mucin concentration promotes mucin fibre aggregation and therefore increase in 
mesh size [2]. 
 
4. Sweeping the dirt away: mucosa and mucus of the respiratory tract 
 
The nasal cavity has an anterior chamber, the nasal vestibule which is followed by the 
respiratory tract which is highly folded providing a high surface area to volume ratio. The 
nasal vestibule consists of keratinized stratified squamous epithelial cells and the respiratory 
regions consisting of the inferior, middle and superior turbinates are made of pseudostratified 
ciliated columnar cells (Figure 5) with microvilli and cilia thereby providing an area of 120 
cm2 [131]. This region produces the maximal nasal secretions because of the presence of 
seromucus glands, the nasolacrimal duct and goblet cells. This region then progresses into the 
nasopharynx where the mucus is ingested for destruction of the pathogens [22, 132]. 
 
The seromucosal glands, which secrete the greater quantity of nasal mucus, comprise both 
mucus cells; secreting the mucus gels, and serous cells, producing a watery fluid. 
Approximately 100,000 seromucus glands exist in the human nose and have essentially the 
same structure as the tracheo-bronchial glands. The number appears to remain constant 
throughout the life-span indicating that an infant has a secretory capacity comparable to that 
of an adult, thereby leading to nasal discharge in a child as opposed to an adult in the event of 
a slight glandular hypersecretion [133]. Accumulation of secretions in the nose may not 
entirely be due to hypersecretion but probably as a result of reduced mucociliary clearance 
rate. Viscous secretions can also arise from paranasal sinuses which have numerous goblet 








Figure 5: Cell types of the nasal epithelium showing ciliated cell (A), non-ciliated cell (B), 
goblet cells (C), gel mucus layer (D), sol layer (E), basal cell (F) and basement membrane 
(G). Reprinted with permission from [22].  
 
 
About 1.5–2 litres of nasal mucus are produced daily. This mucus blanket consists of two 
layers: a lower/pericilliary sol phase which is about 6 μm thick in which the cilia beat and an 
upper mucus gel 4-9 μm thick [5]. The viscosity of both layers affects the ciliary beating and 
the efficiency of transporting the overlying mucus—the mucociliary clearance (MCC). The 
pH of nasal cavity varies between 5.5–6.5 in adults and 5.0–7.0 in infants [135]. 
 
In the human nose, the goblet cell density of the inferior turbinate ranges from 5,000 to 
10,000 cells/mm2, similar to that of maxillary sinus mucosa. Submucosal gland density 
ranges from 1000 to 2000 cells/mm2 in human inferior turbinate and maxillary sinus mucosa.  
[136]. Membrane-bound mucins have transmembrane and cytoplasmic domains that anchor 
the molecules to the apical cell membrane where they participate in functions such as 
structural barrier formation, cellular adhesion, pathogen binding and signal transduction. 
Extracellular units of membrane-bound mucins can be released from the plasma membrane 
into the mucus layer by proteolytic cleavage or by shearing forces [137, 138]. In airway 
epithelial cells MUC1 is a receptor for Pseudomonas aeruginosa flagellin and it also inhibits 
TLR - 5 (toll like receptor) signalling and IL-8 release. Mucins interact with and inhibit the 
effects of cationic inflammatory proteins such as leucocyte elastase and lysozyme. The 
negatively charged carbohydrate of mucins may protect against proteolysis caused by 
cationic inflammatory proteins and bacterial enzymes [139]. 
 
Mucus can crosslink and produce a viscoelastic gel that can form a mechanical coupling with 
cilia and be transported through them. Nasal secretions are comparably lower in viscosity 
than tracheobronchial secretions, but a comparable elasticity is more important than viscosity 
for mucus transport. It is reported that if the sol layer of mucus is too thin, the viscous surface 
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layer will inhibit the ciliary beating, and if the sol layer is too thick, mucociliary clearance is 
impaired because contact with cilia is lost [135]. 
 
There are two well differentiated histological regions along the respiratory tract; the 
conducting airways and the alveolar region for gas exchange which make up for a total 
surface area of 100 m2 [140]. The conducting airway epithelium (in the trachea, bronchi and 
bronchioles) is pseudo-stratified and columnar in nature, and is formed by ciliated, basal and 
secretory cells. Ciliated cells make-up to approximately half of the epithelial surface. The 
structure of the airway epithelium in the distal bronchioles is more cuboidal and non-ciliated 
in nature. The protective mucus layer that covers the epithelium also progressively reduces in 
thickness as the alveolar region is approached, decreasing from a thickness of 10–30 μm at 
tracheal level, to 2–5 μm in the smaller bronchi. Alveolar epithelium consists of type I 
pneumocytes which are thinner (0.1–0.3 μm) to allow efficient gas exchange and type II 
secrete surfactant, a mixture of phospholipids and proteins which line the alveoli. The main 
function of surfactant is to avoid alveolar collapse by reducing the surface tension within the 




4.1 Nasal mucociliary clearance and mucins in health and disease 
 
Cilia beat about 1000 times per minute, with the direction of ciliary beating being backwards 
thereby conveying the mucus with its trapped inhaled particles (allergens, bacteria, viruses, 
toxins, etc.) to the nasopharynx for ingestion. This prevents it from reaching the lungs. An 
optimal movement of cilia combined with mucus rheological properties are required for 
effective and efficient MCC [56]. 
 
The inferior turbinate is the largest of all turbinates. Its length, on average is 48.7 mm in men, 
and 47.3 mm in women  [142]. Studies on healthy subject have shown that 80% exhibit 
clearance rates of 3-25 mm/min (average 6 mm/min) [143]. The mucus lining is renewed 
approximately every 20 minutes [144]. The mean mucociliary clearance rate in healthy 
children is 11.1 ±  3.5 mm/minute and 12.7 ± 5.2 mm/minute for healthy adults (18-60 years) 
[12]. It was also found that mucociliary clearance rate was reduced to approximately 30% in 
comparison to the healthy situation in almost all disease conditions, including chronic 
sinusitis, allergic rhinitis and also in smokers. An increased ciliary beat frequency and higher 
mucus production can contribute to increase the MCC. On the other hand, a decrease in 
mucus viscosity, environmental conditions such as temperatures (</> 23 ͦ C), sulphur dioxide 
inhalation and cigarette smoking can decrease the MCC [22, 145].  
 
Nasal mucus is apparently more viscoelastic than tracheobronchial mucus with nasal mucus 
from healthy subjects exhibiting reducing viscosities at increasing shear frequencies. In 
patients with rhinitis or bronchitis, the viscoelasticity of nasal mucus decreases dramatically, 
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resulting in decreased clearance [146, 147]. Nasal MCC is significantly reduced in chronic 
sinusitis in both man and rabbit [148]. Viscoelasticity of chronic sinusitis (CS) mucus has 
been attributed to increased mucin glycoproteins, which was supported by the reduced 
viscosity but not elasticity of nasal mucus in CS patients treated with mucolytic drugs, such 
as serratiopeptidase or L-cysteine ethyl ester hydrochloride. The ratio of viscosity (η) to G 
(elastic modulus) decreased when serratiopeptidase was orally administered to chronic 
sinusitis patients over a 4 week period thereby increasing the mucociliary transport rate. [16, 
149, 150]. 
 
MUC5AC is the predominant mucin in the human airways and its gene expression and 
production is induced in response to inflammatory stimuli. Bacterial, viral (rhinovirus), 
chemicals, pollutants, proteases and inflammatory cytokines upregulate mucin gene 
expression during sinonasal inflammation. Pro-inflammatory cytokines (TNF-α, IL-1β) and 
Th2 cytokines (IL-4, IL-9 and IL-13), proteases (neutrophil and leucocyte elastase) and 
histamine stimulate mucin production in vivo [151] and Th2 cytokines and TNF-α alter the 
glycosylation and sialylation of secreted mucins [110, 152]. Increased negatively charged 
mucins have an inhibitory effect against cationic inflammatory proteins and bacterial 
enzymes, contributing to the  defence mechanisms to epithelial injury [139]. On the other 
hand, mucin overproduction facilitates bacterial adherence, entrapment and removal by 
mucociliary clearance [36]. It is not yet clear if there are changes in numbers of goblet cells 
in allergic rhinitis (AR) and chronic rhinosinusitis (CRS). However, the number of 
submucosal glands doubles in CRS patients and also rabbit models of sinus infection [136, 
144]. MUC 5AC and MUC2 are the primarily secreted mucins by goblet cells and MUC5B is 
secreted by the mucus cells.  MUC 2, -5AC (highest contribution) and -5B expressions are 
upregulated during airway inflammation (allergic rhinitis and chronic sinusitis) in humans. 
[153]. 
 
In a study by Voynow and colleagues, superficial nasal epithelial cells from normal, cystic 
fibrosis (CF) and allergic rhinitis individuals were used to study the expression of the mucin 
genes MUC5/5AC, MUC2 and MUC1 [154]. These are the preferred cells due to their 
similarity in expression of the CFTR mRNA at levels equivalent to the lower respiratory 
epithelium and free from infection and chronic inflammation. MUC5/5AC gene expression 
was greater than MUC2/MUC1 for all subject groups. In addition, in situ hybridization 
studies revealed that MUC1, MUC2, and MUC5AC genes are expressed primarily in the 
superficial epithelium of nasal turbinates, an expression pattern similar to that of the lower 
respiratory tract [155]. MUC2 mRNA levels were similar among subject groups although 
these results differed from another study by Li and co-workers who suggested increased 
levels of MUC2 mRNA in CF nasal cells compared with controls [9]. This difference can be 
attributed to the fact that all CF subjects in the study by Li et al. were enrolled in a gene 
therapy trial and had received either CFTR cDNA – liposome complexes or liposome alone 






4.2 Challenges in nasal drug delivery 
 
Despite the advantages in nasal drug delivery, limitations exist that must be considered in the 
potential delivery of drugs through this route. The movement resulting from mucociliary 
clearance inhibits drug absorption since contact of formulations with the absorptive surface is 
dramatically reduced. Calcium depletion or blocking calcium activity leads to loss of ciliary 
beating, decreasing clearance. This has a strong implication in nasal mucoadhesive drug 
delivery. Some mucoadhesive polymers like polyacrylic acids chelate calcium ions and lead 
to reduced CBF and longer MCC time [156]. The nature of the mucus barrier also limits drug 
diffusion and potential absorption. The low fluid volume of the nasal cavity restricts the 
potential volume that can be administered to 100–150 µl, posing problems to the 
administration of high doses of poorly water-soluble drugs [157]. Techniques have been used 
to overcome these obstacles, including synthesis of more soluble prodrugs, use of penetration 
enhancers or use of bioadhesive polymers and protease inhibitors to increase the permeability 
of the mucosa to the drug, increase residence time within the nasal cavity and to protect 
against enzymatic degradation [158]. Furthermore, an animal model closest to humans in 
terms of administration volume and clearance rate is also necessary, and the Beagle dog’s 




4.3 Lower respiratory mucus and mucins in health and disease 
 
In the conducting airways of the lung, the mucus barrier possesses gel-sol characteristics and 
is organized in two differentiated layers. The upper layer of the mucus, exposed to the airway 
lumen, presents a high viscosity (gel) and acts as a potent sticky filter for inhaled particulate 
matter. On the other hand, the lower layer, also termed the periciliary fluid, is considered a 
watery (sol) layer and is known as gel on liquid layer [160] This layer allows the cilia to beat 
and recover, so that the rather thick mucus blanket can be propelled towards the proximal 
airways for gastric clearance [160, 161]. Mucociliary clearance rates of 10 – 100 μm s-1 have 
been measured in the human trachea and the thickness of about 10-30 μm is justifiable by the 
small quantity, 10 ml of mucus secreted each day [162, 163].  The clearance of inhaled 
foreign matter trapped within the mucus gel occurs in 15 minutes to 2 hours after inhalation 
[164]. 
 
Five major mucins are expressed in the airways: MUC1, MUC4, MUC5AC, MUC5B, and 
MUC16 [37]. Of these, MUC1, MUC4 and MUC16 are cell membrane bound mucins. Some 
of the proposed roles for membrane-associated mucins include intracellular signal 
transduction pathways, control of inflammation and immune responses, and regulation of cell 
differentiation and proliferation. On the other hand, MUC5AC and MUC5B are the most 
important secreted mucins of the airways and secretion is modulated by inflammatory factors 
such as neutrophil elastase, bacteria, and cytokines [5]. MUC5AC is produced and secreted 
by goblet cells [165], whereas MUC5B is mainly produced by submucosal glands [37]. 
MUC7, a small mucin that lacks domains and does not form a gel, is secreted by a subset of 
serous cells in submucosal glands [166]. The gel-forming MUC5AC and MUC5B are 
primarily responsible for the viscous nature of the luminal mucus mesh which has viscosity 
about 10,000 times higher than that of water [37, 160, 167].  
 
Additionally, a gel on brush model has been postulated in which the pericilary layer (PCL) is 
occupied by membrane spanning mucins and mucopolysaccharides densely tethered to the 
airway surface. In this model, MUC1 is at the bottom of the PCL while MUC4 spans the 
entire PCL giving it a brush like appearance. This prevents mucus penetration and entry into 
the periciliary space. The gel on liquid layer does not explain why the MUC 5AC and MUC 
5B with hydrodynamic radii of ~150-200 nm do not penetrate into the ~200 nm interciliary 
space to form a single layer. In fact, this interciliary space is impenetrable to objects 
significantly smaller than mucins including fluorescent beads of 40 nm diameter [5].  
 
An increase in the viscoelasticity of mucus is usually found in patients with pulmonary 
disorders such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma, 
resulting from decreased hydration and increased fraction of mucins and DNA. In contrast, 
there is a decrease in viscoelasticity in those suffering from rhinitis or bronchitis. The 
mucociliary clearance is the primary mechanism for airway clearance of mucus and is highly 
dependent on the viscoelasticity of the mucus and hydration of the periciliary layer. An 
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intermediate viscoelasticity of the mucus gel and a low viscosity perciliary (sol) layer are 
essential for optimal mucociliary transport [168]. During the ciliary movement a high shear 
rate lowers the viscosity of the mucus hence facilitating its efficient transport. However, if the 
viscoelasticity of the mucus becomes too low, such that the elasticity is insufficient for the 
mucus to withstand gravitational pulling, the mucociliary clearance gets affected and mucus 
slides down into the lung and floods the alveoli. In contrast, when lung disease develops, it 
leads to the development of highly viscoelastic mucus layer and depletion of the sol layer. 
Therefore, the sweeping force exerted by the cilia is incapable of transporting the thick 
mucus and mucociliary clearance ceases, thereby plugging the smaller airways and initiating 
cough reflex as a primary means of transporting mucus upwards [169]. 
 
 
Cystic fibrosis (CF) occurs due to mutations in the CFTR gene. This leads to decreased 
epithelial sodium channel (ENaC) activity decreasing sodium concentration in mucus and 
bicarbonate required for its release and normal viscoelasticity. One theory describes airway 
dehydration as a result of an increase in the mucus osmotic pressure being greater than 
periciliary layer (PCL). Mucus draws water from PCL and beyond a certain concentration, 
the osmotic pressure exceeds that of PCL, initiating the collapse of PCL. In this scenario, 
cilia are unable to beat effectively, mucus adheres to the epithelium causing MCC to cease. 
Mucus stasis leads to airway plugging, chronic bacterial infection, further inflammation and 
airway tissue damage (bronchiectasis) [45].  
 
Mouse models have revealed that MUC5AC provides protection against viral infection by 
acting as a decoy for viral receptors, while MUC5B is essential for MCC and controlling 
bacterial infection [45]. Analysis of CF sputum mucin content has revealed increased 
MUC5AC and MUC5B concentrations (especially following exacerbations) with MUC5B 
being the predominant mucin [170]. Likewise, immunohistochemical analysis has 
demonstrated increased concentrations of MUC5AC and MUC5B in the mucus plugs of CF 
airways when compared to healthy controls, again, with a higher relative abundance of 
MUC5B [171]. In human tissues, histochemical observations showed increased MUC5AC 
and MUC5B staining of goblet cells and mucus cells of submucosal glands respectively, with 
an increase of MUC5AC-positive cells due to goblet cell hyper and metaplasia [172]. 
However, results suggest that CF airway inflammation occurs even in children under 6 
months and could even precede infection. Increased amounts of neutrophils, neutrophil 
elastase and pro-inflammatory cytokines (IL-8) can be detected in broncho-alveolar lavage 
(BAL) [173]. BAL and sputum from adults also contain pro-inflammatory cytokines such as 
TNF-α, IL-1, IL-6, IL-8 and IL-17 compared to non-CF controls [174,] whereas anti-
inflammatory cytokine IL-10 is reduced [175]. Aberrant ion transport and mucus dehydration 
are not the main causes of inflammation and therefore a mechanism inducing this 
inflammation has been investigated. Mutation in the CFTR leads to accumulation of 
misfolded CFTR, resulting in nuclear factor-kB activation and increased IL-8 even in the 
absence of bacteria [176]. In human bronchiolar mucosa, TNF-α increases expression and 
activity of sialyltrasferases and sulfotransferase. This can explain the over sialyation on 
human airway mucins secreted by patients with severe lung infections such as those with CF. 
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Increased IL-6 and IL-8 also increase expression of sialyl transferase, fucosyl transferase 
genes thereby contributing towards increased sialylation and sulfation of airway mucins 
promoting the increased adhesion of Pseudomonas aeruginosa. This coupled with increased 
mucus viscosity, periciliary collapse and stasis leads to lung infection [110, 177, 178].  
Certain diseases and smoking affect the glycosylation of mucins.  Exposure to cigarette 
smoke which leads to chronic obstructive airways disease, causes a shift from an almost 
equal proportion of acidic and neutral mucins to mostly neutral mucins [162].  
 
5. Is the cervical and vaginal mucus similar? 
 
The cervix connects the vagina with the uterus and functioning as an entrance into the female 
endometrial and abdominal cavities. Therefore, a protection mechanism has to be in place to 
avoid external microorganisms to gain access. The vagina wall is structured in a lamina 
propria and an epithelium of non-cornified stratified squamous cells. The thickness of this 
epithelial barrier is higher in puberty and after menopause. The luminal pH decreases after 
puberty to about pH 4-5, depending on the menstrual cycle. The secreted cervical mucus fills 
the opening of the cervix and acts as an important protective barrier preventing pathogens 
from ascending into the uterus. Secreted into the vagina, the mucus is also important as it 
traps microorganisms and flushes these out of the vagina to protect both the uterus and the 
vaginal epithelium. Despite its protective role, the mucus should allow or serve on the other 
hand as vehicle for sperm to migrate at ovulation [179].  
 
 
5.1  Mucins of the cervix and vagina 
 
 
The cervical mucus is a complex secretion originating from the secretory cells of the 
columnar epithelium of the cervix.  Mucus facilitates the sperm movement from the vagina 
till the uterus. It has been shown that the hydration of the mucus, rheological properties and 
glycosylation play a major role on this process. The carbohydrate content of mucin during the 
menstrual cycle seems to be preserved but soluble proteins show a variation along this 
timescale. The secretion rate reaches its peak during the middle of the cycle [180]. The 
secretion of cervical mucus is regulated by the ovarian hormones estrogen and progesterone. 
While the first promotes mucus production the latter inhibits the secretory activity of the 
cervical epithelial cells [181]. 
 
Mucins form a highly viscoelastic mesh acting as a lubricant and a physical barrier for 
microbes at mucosal interfaces [3]. Mucosal epithelial cells express cell surface mucins, such 
as MUC1, MUC4, and MUC16 [76]. Goblet cells produce and secrete gel-forming mucins, 
such as MUC5AC, MUC5B, and MUC6. Both type of mucins, cell-surface and secreted are 
found in the mucus in the endocervix. Besides the cervical mucus, which flows into the 
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vaginal compartment, the cervicovaginal fluid is composed by vaginal wall transudate, vulvar 
secretions, exfoliated epithelial cells, and secretions from bacterial flora [182]. This mixture 
of cervical mucus and cervicovaginal fluid is designed as cervicovaginal mucus (CVM). In 
consequence of the different composition is likely that the mucin structure and barrier 
function in CVM differs from that in CM secreted at the endocervix [182, 183]. 
 
 
The cervical and cervicovaginal mucus play a major role in protection against infections, 
such as those by HIV, by hindering diffusion to the epithelial surface. It has been found that 
cervicovaginal fluid interacts with HIV, favoured at neutral pH (compared to acidic pH), but 
not with 200 nm Pegylated nanoparticles, highlighting the role of lipids and proteins in virus 
on interaction with the protein core of mucins [182]. However, the permeation of pegylated 
particles is also hindered in cervical mucus, suggesting a much more dense mucus network. 
Water content, mucin expression levels, and glycosylation vary throughout the cycle in CM 
[179].  
 
Genotypic differences between individuals that affect the number and type of carbohydrate 
residues on mucins also play a role on protection against pathogens [3]. The viscoelastic 
properties of CM slow down diffusion of HIV-1 increasing the time available for innate 
immune factors to inactivate the virus. Additionally, the mucus movement towards the vagina 




5.2 Mucin and mucus changes during menstrual cycle and disease 
 
The cervix produces about 20-60 mg mucus/day in normal women at reproductive age, 
however, during the midcycle this amount is increase up to 700 mg mucus/day [181]. Despite 
changes in quantity, also physical characteristics such as viscosity and mucin glycosylation 
undergo changes during midcycle. For instance, viscosity and flow elasticity are reduced after 
menstruation to the ovulation time [179, 186]. In fact, altered mucus properties have been 
shown to be a very good predictor of the fertile window [186]. The importance of the cervical 
mucus is also illustrated by the observation that abnormalities of the cervical secretions are 
responsible for infertility in about 5–10% of infertile women [181, 186]. Despite its 
importance, there is still limited biochemical understanding of the composition of the cervical 
mucus and how this is altered during ovulation. Most of the cervical mucus is water (95–
99%), but it also contains a complex mixture of organic components, inorganic ions, 
enzymes, bactericidal proteins, plasma proteins, and especially mucins. In the mucus 2 types 
of proteins can be found: soluble proteins, predominantly albumin and immunoglubulins and 
mucins. During the pre and post-ovulation it has been found an increase of these soluble 
proteins in mucus. Other proteins, such as the enzymes amylase, alkaline phosphatase, 
esterase, aminopeptidase, lactate dehydrogenase and peroxidase can also be found in the 
cervical mucus [186]. 
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In the cervical mucus the gel-forming mucin MUC5B is the major mucin component together 
with MUC5AC. The amount of MUC5B mucin in human cervical mucus varies during the 
menstrual cycle and peaks at ovulation, suggesting that this larger mucin species may be an 
important factor affecting sperm transit to the uterus [187]. All mucins contain large mucin 
domains, also called PTS domains, that are rich in the amino acids serine, threonine, and 
proline and provide a high number of attachment sites for O-linked carbohydrates [187], 
which contribute to the rheological and hydrodynamic properties of mucins. Changes in 
mucin glycosylation during ovulation can lead to modifications in other biochemical 
properties but conflicting results have been reported [188, 189]. 
 
A more recent and comprehensive study showed that the O-glycans of the cervical mucins 
exhibited more than 50 different neutral, sialated, and sulfated oligosaccharides [179]. The 
major changes observed during the menstrual cycle were in the mucin O-glycosylation and at 
ovulation. This was reflected by a relative abundance of neutral oligosaccharides in 
comparison to those acidic. The mucus glycosylation at ovulation could also promote sperm 
movement due to the low sialic acid content of the mucus. Although the composition of the 
mucus seems to be relatively constant, except for the mucin glycosylation, other alterations in 
mucins could contribute to the altered mucus properties.  
 
5.2.1 Cervical mucus role in fertility and disease 
 
Cervical mucus and pH plays a role in sperm survival and fertility. In order to maintain sperm 
viable the optimal pH ranges between 7 and 8.5 with a reduction in motility seen for pH 
below 6. Since the cervical pH is acidic, the higher pH of the semen associated with its buffer 
capacity contributes to the viability of sperm. However, reduction of semen volume or pH 
can affect fertility. Cervical mucus changes can also dramatically affect mobility of sperm 
along the cervical canal [57, 190]. For instance, in chronic cervicitis, the mucus composition 
is changed affecting its structure and thereby impacting sperm movement between the mucus 
mesh [57]. The cervical mucus architecture is not uniform presenting areas of tighter mucus 
mesh, closer to the mucosa and looser mucus regions where shear is higher [190]. 
Lactobacillus species, particularly Lactobacillus iners, is the most abundant bacteria in the 
vagina of premenopausal women [191]. These bacteria produce lactic acid, hydrogen 
peroxide and other antimicrobial molecules which protect against vaginal infections [192, 
193]. L. iners feed on glycan from degraded mucin [192]. 
 
Bacterial vaginosis is a common condition, being mostly asymptomatic. Malodorous is the 
only signal of this condition, reflected by lower levels of Lactobacilli and overgrowth of 
anaerobic and facultative bacteria [191]. A disruption in the mucus architecture, as seen in 
cases of bacterial vaginosis, allows diffusion of virus leading to potential infections [182, 
194]. Different species of Lactobacillus contribute to the diffusion properties of 
cervicovaginal mucus having a significant role on protection against HIV and other sexually 
transmitted infections [195]. Therapeutic interventions leading to re-establishment of 
lactobacilli, for instance, through probiotic or by products that reinforce lactic acid can 
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contribute to a protections against infection [193]. Candida albicans bind to fucosylated 
glycans highlighting the role of these mucins in protection against Candida albicans 
infections [196].  
 
 
5.3 Diffusion across cervical mucus and means to overcome it for improved drug 
delivery 
 
In contrary to early observations, virus and large proteins are able to diffuse across mucus 
[15, 197]. Diffusion of particles, virus and proteins through mucus is dependent on mucus 
mesh size and interactions with the glycoproteins, which can hinder movement within the 
network [31]. For an effective immune surveillance, the antibodies present in the mucus shall 
be able to move freely within the mucus mesh to neutralize pathogens. Large complexes of 
antigen-antibody can then be removed with the renewal of the mucus. Also topical delivery 
of antibodies to protect against sexually transmitted diseases or fertilization has been proven 
as an useful strategy [197]. Similarly, antibodies directed against intestinal pathogens have 
shown a protective function of the underlying epithelium [198]. In human midcycle cervical 
mucus samples, the diffusion coefficients of most of the tested fluorescent labelled proteins 
(exogenous), including IgG were similar to diffusion coefficients in buffer, indicating a lack 
of barrier function given by the mucus [15, 197] . However, IgM diffusion is significantly 
slowed down in mucus, as well as IgM without the respective Fabs, suggesting that the Fc 
region is the main responsible for the low binding affinity to mucins [15].  
 
Others have demonstrated that a fraction of endogenous IgG and IgA can differentially bind 
to cervical (CM) and cervicovaginal mucus (CVM). IgG is found to be stable associated with 
both CM and CVM whereas IgA is not associated with CVM [199]. This suggests that the 
number of binding sites may be limited, explaining why exogenous applied IgGs can diffuse 
quickly through cervical mucus. In the gastrointestinal tract, binding of IgG can occur by 
direct binding to mucins or through binding to FcGBP present in the mucus [200, 201]. The 
binding of IgG to mucins can contribute to the entrapment of pathogens such as HIV, being 
shed with the mucus renewal and preventing an infection of the underlying epithelium. 
Surprisingly, even capsid virus-like particles such as human papilloma virus (55 nm, 
20000kDa) and Norwalk virus (38 nm, 10000 kDa) diffuses unhindered through cervical 
mucus. In contrast, diffusion of herpes simplex virus (180 nm) is strongly reduced in cervical 
mucus, suggesting that besides a mesh size of mucus, also a low binding affinity with mucins 
contributes to this effect. Furthermore, polystyrene particles (1000 nm) have been shown to 
bind strongly to mucin, hindering diffusion. It has been suggested that a combination of 
positive and negative charges prevents adhesion on the surface of proteins plus lack of 
hydrophobic exposed regions [202] . 
 
 
Among the conventional vaginal drug delivery systems are vaginal tablets, foams, gels, 
suspensions and vaginal rings. The latter have been developed to deliver the contraceptive 
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steroids in a sustained release fashion [191].  The complex interactions between mucins and 
other molecules and fast diffusion of virus particles with neutral net charges have inspired the 
design of novel carrier systems with improved diffusion through mucus in order to increase 
bioavailability and decrease degradation in the luminal conditions [15]. In this regard, mucus 
penetrating particles, exhibiting a surface densely covered with polyethyleneglycol have been 
developed [17, 203]. The lower molecular weight and higher density of PEG on the surface 
resulted in faster diffusion rate in human cervicovaginal mucus [204].  Ex-vivo and in vivo 
rapid diffusion through mouse vaginal and colorectal mucus has been observed with 
nanoparticles grafted with PEG with 40 kDa [205]. Furthermore, it has been shown that hypo 
tonicity of the applied formulation improves distribution and diffusion of the particles 
through the cervicovaginal mucus [206, 207]. On the other hand, it has been recently 
highlighted the possibility to generate anti-PEG IgG and IgM, which can cross-link PEG 
coated particles limiting its diffusion through  mouse cervicovaginal mucus, even when the 
particles are prepared as hypotonic suspension [208]. 
 
6. Protecting the sclera: the pre-corneal tear film and conjunctival epithelium 
 
The  eye (figure 6) is covered by a wet surface epithelium over coating the cornea, 
conjunctiva and other inner surfaces, which has similar functions as other wet surfaces, 
including lubrication, protection against damage, fluid loss and pathogens infection [209, 
210]. The epithelium of the cornea also plays a role in the transmission of light and 
refraction. The tear film is composed by an outer lipid layer and by the inner aqueous layer 
which is composed by anti-bacteria proteins and mucins. Besides contributing to retain water, 
mucins also function as a retention mesh to bacteria and particles to protect the underlying 
epithelium [209]. Additional functions such as barrier function, cell growth and 
differentiation, cell-cell and cell-matrix interactions, and signal transduction have been 
attributed to ocular membrane-associated mucins [39, 211]. 
 
The cornea surface is layered by a non-keratinized stratified squamous epithelium, disposed 
in regular 5-7 cells layers, highly specialized in light reflections and transmittance, and in rats 




6.1 Formation of the tear film 
 
The epithelium of the conjunctiva coats the inner surface of the eyelid and is similar in 
structure to the corneal epithelium, however the numbers of cell layers ranges between 3 and 
12 [209]. Intercalated in between the epithelial cells are Goblet cells, in higher numbers in 
humans near the exit of the nasolacrimal duct [213]. Goblet cells of the conjunctiva extend 
throughout the thickness of the stratified epithelium to the apical surface, where MUC5AC is 
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released. MUC5AC, a heavily glycosylated mucin is released from the mucin granule in a 
mechanism dependent on high concentration of cations, such as calcium. In contrast to the 
mucins in the gut, MUC5AC at the ocular surface does not form a continuous layer but 
moves over the surface of the epithelium. MUC 16, a transmembrane mucin seems to play a 
role in MUC5C discharge [214]. Goblet cells form tight junctions with stratified epithelial 
cells and express claudin 2, a pore-former type of claudin which has been suggested to be 
involved in the regulation of fluid to and from the tear film [214]. While in rats and mice, 
there are clusters of Goblet cells, in rabbits and humans they are found isolated [215]. The 
submucosal lacrimal glands and Meibomian glands (in the lid)  are responsible for the 





Figure 6: Diagram of the anterior portion of the eye (A), stratified epithelium of the cornea 
(B), stratified epithelium of the conjunctiva (C), epithelia of the lacrimal gland (D). Reprinted 
with permission from Gibson, 2003 [209]. 
The human ocular surface produces two secreted mucins, the gel-forming MUC5AC  and the 
soluble MUC7 [216]. The goblet cells of the conjunctiva epithelium contribute the most to 



















Figure 7: Diagram of the tear film and its interface with the ocular surface epithelium. 
Reprinted with permission from [217]. 
 
The transmembrane mucins, MUC1, MUC4, and MUC16, have been found at the ocular 
surface [39, 210], namely at the most apical side of the stratified squamous epithelium of the 
cornea and conjunctiva. Other mucins have been also observed on the human conjunctiva, 
such MUC13, MUC15, and MUC17 [211]. MUC20, a transmembrane mucin was found on 
the extent of the corneal and conjunctiva epithelial cells and is involved in keeping the ocular 
surface homeostasis [211]. Among the gel-forming mucins, MUC5AC (the most abundant), 
MUC2 (less abundant) is produced and secreted by the goblet cells of the conjunctiva while 
the soluble MUC7 is produced by the lacrimal gland and by the stratified epithelium of the 
conjunctiva [216, 218, 219]. The lacrimal gland besides MUC 7 also produces other mucins, 
such as MUC1, MUC4, MUC5AC, MUC5B, MUC6 and MUC7, whose levels seem to 
change with age [220]. 
 
6.2 Ocular mucins in health and disease 
 
The apical membranes in the cornea and conjunctiva show fingerlike ridges (microplicae) 
which increases its surface area covered with the glycocalyx, extracellular domains of the 
membrane associated mucins [213]. The mucus component (secreted mucins plus membrane 
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bound mucins have been estimated to be 3 – 30 µm thick in different animal models using 
confocal microscopy and interferometry [221]. The secreted mucins move freely contributing 
to lubrication and removal of foreign particles from the surface of the eye. During blinking, 
the mucus and tear film eventually move out towards the nasolacrimal duct [209]. Similarly, 
membrane bound mucins are shed off as the epithelial cells age and the microplicae structure 
is lost [213].  
 
The secreted mucins MUC5AC and MUC 7 contribute to the lubrication and protection of the 
epithelial by binding fungi and yeast and to remove particulate material away [209]. MUC7 
also facilitates the transportation of bactericidal proteins from the lacrimal gland to the tear 
film [216]. It is not completely understood if the different membrane bound mucins share 
functions or each is responsible for a particular function. These mucins contribute to water 
retention at the surface of the cornea and conjunctiva and also to lubricate, promoting 
disadhesion, and avoiding strong interactions between the eye lid conjunctival epithelium to 
the cornea. Due to its less dynamic nature, they provide a continuous protective barrier 
against pathogens [39, 213]. MUC1 and MUC 4 seems to be also involved in signal 
transduction and growth control [188].  
 
Changes in mucins at the ocular surface during expression, translation or post-translational 
(i.e. glycosylation) often leads to allergic, non-autoimmune dry eye, autoimmune dry eye and 
infections [39]. In the case of allergic diseases, such as atopic keratoconjunctivitis (AKC) and 
vernal keratoconjunctivitis (VKC), changes occur in both types of mucins. Patients with 
atopic keratoconjunctivitis exhibit a loss of Goblet cells and decreased levels of MUC5AC 
and increase in expression of MUC1, MUC2 and MUC 4 [222, 223]. Reduced levels of 
expressed MUC16 have also been reported in atopic keratoconjunctivitis [222]. Using a 
mouse model of allergic conjunctivitis a lower number of Goblet cells and MUC5 was found 
in the conjunctiva after repetitive application of allergens [224]. On the other hand, an 
increased level of Goblet cells and increased amounts of MUC5AC is a landmark of vernal 
keratoconjunctivitis as an over-response to clear-up allergens from the ocular surface. This is 
accompanied by ocular inflammation and neutrophils infiltration [225] .  
 
 
Drying or keratinization of the ocular surface, such as manifested in dry eye syndrome 
(aqueous or lipid deficient and the Sjögren syndrome) [39, 209, 223, 226] find their roots in 
alterations at the mucin level. Expression of MUC4, MUC5AC and MUC5B was found to be 
higher in the glands of elderly women receiving treatment for dry eye as compared to the 
absence of treatment [227]. Furthermore, reduced Goblet cells and reduced levels of 
MUC5AC in the tear fluid and conjunctiva have been reported in patients with Sjögren 
syndrome, a systemic autoimmune disease, most prevalent in women [226]. Also, MUC19 
has been reported to be reduced [228]. Interfering with the mechanism of membrane bound 
and secreted mucin expression to promote expression could offer therapeutic advantages in 
the treatment of dry eye syndrome [229]. Also, diseases leading to cicatrization such as the 
ocular cicatricial pemphigoid and Stevens–Johnson syndrome can be caused by changes in 
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mucins. Alteration of O-glycosylation of mucins, due to changes in glycosyltransferases has 
been reported as a cause for ocular cicatricial pemphigoid [230]. 
 
 
6.3 Implications of ocular mucins on drug delivery 
 
Drug delivery to the eye offers the advantage of the easy access for application, however due 
to the anatomy and rapid blinking and tear drainage, the residence time of the drug at the 
absorbing surface, mostly the cornea, bioavailability and delivery to the posterior segment of 
the eye is limited [231]. The clearance of topically applied solutions occurs within 15 to 30 
seconds. Therefore, the resulting intraocular bioavailability of topically applied drugs to the 
anterior chamber is less than 5%. The cornea is structured into the epithelium, stroma, rich in 
water and endothelium. Most of the drugs delivered to the eye are drops, ointments, 
hydrogels and extended release devices, such as contact lens for local action [232]. 
Absorption through the conjunctiva offers an entry into the bloodstream. The cornea and 
conjunctiva are covered with the tear fluid, which besides secreted mucins contains 
electrolytes, albumin and lysozyme and on its top lays a lipid barrier (secretion by the 
Meibomian glands).  In normal conditions, only a very small volume of administered drugs, 
circa 30 µl, can be applied without overflowing [232, 233].  The composition of eye drops 
can enhance tear flow reducing drug concentration at the epithelium. Increasing the viscosity 
of eye drop vehicles, using polymers that can also bind to mucins of the eye drops vehicle can 
have a positive impact on drug retention, however the effect is limited [234]. The secreted 
mucins do not form a static mucus layer on top of the cornea and therefore retention of the 
formulation is limited by the shed-off of mucins along with the tear fluid. Soft contact lenses 
have also been used to deliver drugs to the ocular surface and is reviewed elsewhere [232, 
235, 236]. Mucin expression is not altered by long term contact lens wearing, however both 
shed transmembrane and secreted mucins can adhere to contact lens [237]. An optimal ocular 
delivery system should allow zero-order release kinetics, cause minimal inflammation and 
irritation, minimal loss in the storage process, easy handling and have the least interference 
with the patient’s vision. Kala Pharmaceutics is developing ocular formulations based on 
mucus penetrating particles, which are able to rapidly penetrate the mucus and avoiding 
clearance, increasing the exposure to the epithelial cells. The concept has been successfully 
demonstrated in both rabbits and minipigs, resulting in therapeutic drug levels in the back of 




This review has served to highlight the adaptations of mucosal surfaces and mucus to 
promote their optimal and healthy functioning. Factors including mucus hydrophobicity, 
viscoelasticity, turnover and thickness, as well as epithelial dynamics (such as mucociliary 
clearance in the respiratory tract) work together to enable mucus to function as a tenacious 
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semi-permeable barrier. However, this useful mucus barrier can also create a slippery slope 
of challenges to mucosal drug and gene delivery leading to poor local or systemic uptake. 
Therefore, an understanding of its origins, physiology, biochemistry and the nature of the 
epithelia bears importance and has been the key focus of this review. This fundamental 
information will enable effective drug delivery systems to be designed, enhancing drug 
penetration through the mucus barrier to reach the underlying epithelia. There is no single 
factor that can be overcome to easily promote the increased penetration of drugs or delivery 
systems through the overlying epithelial mucus barrier. However, attempts have been made to 
circumvent these limitations: mucophilic nanoparticles have shown promise in terms of fast 
diffusion rates through the mucus layer. However, their ability to beat the rate of secretion 
and travel upstream to reach, adhere and sufficiently deliver the payload or penetrate the 
epithelium is yet to be understood. Furthermore, virus mimetic mucus-penetrating 
nanoparticles have been designed for cervico-vaginal and ocular delivery. It is clear that by 
gaining a detailed understanding of the mucus barrier, more effective mucosal drug delivery 
systems can be designed, resulting in rewarding outcomes in terms of desired efficacy rates 
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Patients with Sjögren Syndrome. Investigative Ophthalmology & Visual Science, 
2002. 43(4): p. 1004-1011. 
227. Schäfer, G., et al., Tränendrüsenassoziierte Muzine. Der Ophthalmologe, 2005. 
102(2): p. 175-183. 
228. Yu, D.F., et al., MUC19 expression in human ocular surface and lacrimal gland and 
its alteration in Sjögren syndrome patients. Experimental Eye Research, 2008. 86(2): 
p. 403-411. 
229. Watanabe, H., Significance of Mucin on the Ocular Surface. Cornea, 2002. 21: p. 
S17-S22. 
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Figure 4: Assembly of the MUC2 mucin in the goblet cell. ER, endoplasmic reticulum; 
TGN, trans-Golgi network. Reprinted with permission from [46].  
Figure 5: The mucin-release mechanism in the small intestine. Reprinted with permission 
from [51]. 
Figure 6: The organization of epithelium and mucus in the gastrointestinal tract. Reprinted 
with permission from [59]. 
Figure 4: Model of how a fiber-deprived gut microbiota mediates degradation of the colonic 
mucus barrier and heightened pathogen susceptibility. Reprinted with permission from [127]. 
 
Figure 5: Cell types of the nasal epithelium showing ciliated cell (A), non-ciliated cell (B), 
goblet cells (C), gel mucus layer (D), sol layer (E), basal cell (F) and basement membrane 
(G). Reprinted with permission from [22].  
 
Figure 6: Diagram of the anterior portion of the eye (A), stratified epithelium of the cornea 
(B), stratified epithelium of the conjunctiva (C), epithelia of the lacrimal gland (D). Reprinted 
with permission from [209]. 
 
Figure 7: Diagram of the tear film and its interface with the ocular surface epithelium. 
Reprinted with permission from [217]. 
 
 
 
